Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials 🔗 Access full article via Journal of Allergy and Clinical ImmunologyAI SummaryThe content of the article is not provided.Share:TwitterFacebookEmailRedditMoreLinkedInWhatsAppTelegramMastodon
